PALLAS investigates the efficacy and safety of the addition of two years of adjuvant palbociclib to ET in patients with HR+ human epidermal growth factor receptor 2 early breast cancer. Large clinical trials are conducted to assess the usefulness of CDK4/6i in the curative early disease setting. The addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) such as palbociclib to endocrine treatment (ET) has improved outcomes for patients with metastatic hormone receptor-positive human epidermal growth factor receptor 2–negative breast cancer. 1Medical University of Vienna, Comprehensive Cancer Center, Vienna, AustriaĢABCSG, Austrian Breast and Colorectal Cancer Study Group, Vienna, AustriaģAlliance Statistics and Data Center and Mayo Clinic, Phoenix, AZĤHospital General Universitario Gregorio Marañón, Madrid, SpainĥGEICAM Spanish Breast Cancer Group, Madrid, SpainĦDana-Farber Cancer Institute, Boston, MAħDepartment of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center of Clinical Cancer and Immunology Trials Cancer Cluster Salzburg, Salzburg, AustriaĨCentral West Cancer Care Centre, Orange Health Service, Orange, NSW, Australiaġ0Breast Cancer Research Centre-WA & Curtin University, Perth, Australiaġ1Department of Gynecology and Gynecological Oncology, Medical University of Vienna, Vienna, Austriaġ2Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, INġ3IEO, European Institute of Oncology, IRCCS, Milan, Italyġ4Kaiser Permanente Vallejo Medical Center, Vallejo, CAġ5National Institute of Oncology, Budapest, Hungaryġ6The Institute of Cancer Research, London, United Kingdomġ7Vanderbilt University Medical Center, Nashville, TNġ8The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, PolandĢ1NSABP Foundation, Inc, and The UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PAĢ2Hospital Universitari Sant Joan de Reus, Reus, SpainĢ3University of California San Francisco Comprehensive Cancer Center, San Francisco, CAĢ4Hospital Universitario de Burgos, Burgos, SpainĢ6Hospital Universitari Son Espases, Palma de Mallorca, SpainĢ7Vall d'Hebron Institute of Oncology, Barcelona, Spainģ2University of Pennsylvania, Philadelphia, PA

Rafael ramirez carreno fortuna